

Interleukin Inhibitors Market Rapidly Advances In Biosimilars, Boosting Growth At Rate 18%

The Business Research Company's Interleukin Inhibitors Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026


LONDON, GREATER LONDON, UK, April 6, 2022 /EINPresswire.com/ -- Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative. Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors. For instance,

biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs. This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.

The [global interleukin inhibitors market size](#) is expected to grow from \$26.95 billion in 2021 to \$31.73 billion in 2022 at a compound annual growth rate (CAGR) of 17.7%. The growth in the interleukin inhibitors market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The interleukin inhibitor market is expected to reach \$57.87 billion in 2026 at a CAGR of 16.2%.

Read more on the Global Interleukin Inhibitors Market Report

<https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report>



An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market growth. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses preventing damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. According to the interleukin inhibitors market overview, these growing numbers of pipeline drugs will drive the market growth upon approval.

Major players covered in the global interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.

TBRC's global interleukin inhibitors market research report is segmented by type into il-17, il-23, il-1, il-5, il-6, others, by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others, by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

[Interleukin Inhibitors Global Market Report 2022](#) – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a interleukin inhibitors market overview, forecast interleukin inhibitors market size and growth for the whole market, interleukin inhibitors market segments, geographies, interleukin inhibitors market trends, interleukin inhibitors market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Interleukin Inhibitors Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3469&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Psoriasis Global Market Report 2022 – By Drug class (Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor), By Distribution Channel (Hospitals, Retail Pharmacies, E-Commerce), By Drug Types (Small molecules, Biologics), By Route Of Administration (Oral, Topical, Injectable), By Disease Indication (Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report>

Psoriatic Arthritis Treatment Global Market Report 2022 – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologics), By

Route Of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report>

Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers), By Therapy (Preventive, Curative), By Route Of Administration (Oral, Inhaled, Intravenous, Subcutaneous), By Age Group (Below 5, 5-14, 15-60, Above 60), By Prescription (Prescription, Over The Counter (OTC)), By Drug Type (Branded, Generic) And By Region, Opportunities And Strategies – Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/567656764>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.